ivermectin (Soolantra®)

Reference No. 1627

Publication date:

01/04/2016

Appraisal information

ivermectin (Soolantra®) 10 mg/g cream

Company:	Galderma (UK) Ltd
BNF category:	Skin
NMG meeting date:	20/01/2016
AWMSG meeting date:	24/02/2016

Submission Type:	Full Submission
Status:	Recommended
Advice No:	0216
Ratification by Welsh Government:	24/03/2016

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

Ivermectin (Soolantra®) is recommended as an option for use within NHS Wales for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.

Final Appraisal Recommendation (FAR)

Download

ivermectin (Soolantra) 1627 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

ivermectin (Soolantra) 1627 ASAR

Clinical Expert (CE) Summary

Download

ivermectin (Soolantra) 1627 CE summary